Our top pick for
Cassava Sciences Inc is a biotechnology business based in the US. Cassava Sciences shares (SAVA) are listed on the NASDAQ and all prices are listed in US Dollars. Cassava Sciences employs 11 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$49.69|
|52-week range||$6.70 - $146.16|
|50-day moving average||$58.62|
|200-day moving average||$67.08|
|Wall St. target price||$159.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.38|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-05)||N/A|
|1 month (2021-09-16)||13.06%|
|3 months (2021-07-16)||-37.96%|
|6 months (2021-04-16)||42.58%|
|1 year (2020-10-16)||374.14%|
|2 years (2019-10-16)||3,907.26%|
|3 years (2018-10-16)||4,006.61%|
|5 years (2016-10-14)||6,708.71%|
|Gross profit TTM||$-3,053,000|
|Return on assets TTM||-5.19%|
|Return on equity TTM||-8.45%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
There are currently 8.9 million Cassava Sciences shares held short by investors – that's known as Cassava Sciences's "short interest". This figure is 12.4% up from 7.9 million last month.
There are a few different ways that this level of interest in shorting Cassava Sciences shares can be evaluated.
Cassava Sciences's "short interest ratio" (SIR) is the quantity of Cassava Sciences shares currently shorted divided by the average quantity of Cassava Sciences shares traded daily (recently around 11.2 million). Cassava Sciences's SIR currently stands at 0.79. In other words for every 100,000 Cassava Sciences shares traded daily on the market, roughly 790 shares are currently held short.
However Cassava Sciences's short interest can also be evaluated against the total number of Cassava Sciences shares, or, against the total number of tradable Cassava Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cassava Sciences's short interest could be expressed as 0.22% of the outstanding shares (for every 100,000 Cassava Sciences shares in existence, roughly 220 shares are currently held short) or 0.2369% of the tradable shares (for every 100,000 tradable Cassava Sciences shares, roughly 237 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cassava Sciences.
Find out more about how you can short Cassava Sciences stock.
We're not expecting Cassava Sciences to pay a dividend over the next 12 months.
Cassava Sciences's shares were split on a 1:7 basis on 9 May 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cassava Sciences shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Cassava Sciences shares which in turn could have impacted Cassava Sciences's share price.
Over the last 12 months, Cassava Sciences's shares have ranged in value from as little as $6.7 up to $146.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cassava Sciences's is 0.9196. This would suggest that Cassava Sciences's shares are less volatile than average (for this exchange).
Cassava Sciences, Inc. , a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.